Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier
Advanced Healthcare Materials · 2024-06 · 13 (14)
DOI: 10.1002/adhm.202303654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024-03. Verfasst von Julia Werner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany. Hauptthemen laut MEDLINE: Vancomycin, Liposomes, Anti-Bacterial Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Phospholipid Research Center.
Abstract (Originalsprache)
Oral delivery of peptide therapeutics faces multiple challenges due to their instability in the gastrointestinal tract and low permeation capability. In this study, the aim is to develop a liposomal nanocarrier formulation to enable the oral delivery of the vancomycin‐peptide derivative FU002. FU002 is a promising, resistance‐breaking, antibiotic which exhibits poor oral bioavailability, limiting its potential therapeutic use. To increase its oral bioavailability, FU002 is incorporated into tetraether lipid‐stabilized liposomes modified with cyclic cell‐penetrating peptides on the liposomal surface. This liposomal formulation shows strong binding to Caco‐2 cells without exerting cytotoxic effects in vitro. Pharmacokinetics studies in vivo in rats reveal increased oral bioavailability of liposomal FU002 when compared to the free drug. In vitro and in vivo antimicrobial activity of FU002 are preserved in the liposomal formulation. As a highlight, oral administration of liposomal FU002 results in significant therapeutic efficacy in a murine systemic infection model. Thus, the presented nanotechnological approach provides a promising strategy for enabling oral delivery of this highly active vancomycin derivative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Heidelberg University Hospital, 69120, Heidelberg, Germany.
- Institute for Molecular Infection Biology, University of Würzburg, 97080, Würzburg, Germany.
- Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120, Heidelberg, Germany.
- Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, 69120, Heidelberg, Germany.
ORCID-Profile: Philipp Uhl
Förderung
- Bundesministerium für Bildung und Forschung
- Phospholipid Research Center
Zitieren
APA
Werner, J., Umstätter, F., Hertlein, T., Mühlberg, E., Beijer, B., Wohlfart, S., Zimmermann, S., Haberkorn, U., Ohlsen, K., Fricker, G., Mier, W., & Uhl, P. (2024). Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier. Advanced Healthcare Materials, 13(14). https://doi.org/10.1002/adhm.202303654
Vancouver
Werner J, Umstätter F, Hertlein T, Mühlberg E, Beijer B, Wohlfart S, et al. Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier. Advanced Healthcare Materials. 2024;13(14). doi:10.1002/adhm.202303654
BibTeX
@article{Werner2024,
author = {Werner, Julia and Umstätter, Florian and Hertlein, Tobias and Mühlberg, Eric and Beijer, Barbro and Wohlfart, Sabrina and Zimmermann, Stefan and Haberkorn, Uwe and Ohlsen, Knut and Fricker, Gert and Mier, Walter and Uhl, Philipp},
title = {Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {14},
doi = {10.1002/adhm.202303654}
}
EUVIMED